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mTORC1-independent Raptor prevents hepatic
steatosis by stabilizing PHLPP2
KyeongJin Kim1, Li Qiang1, Matthew S. Hayden2,3, David P. Sparling4, Nicole H. Purcell5 & Utpal B. Pajvani1
Mechanistic target of rapamycin complex 1 (mTORC1), defined by the presence of Raptor, is
an evolutionarily conserved and nutrient-sensitive regulator of cellular growth and other
metabolic processes. To date, all known functions of Raptor involve its scaffolding mTOR
kinase with substrate. Here we report that mTORC1-independent (‘free’) Raptor negatively
regulates hepatic Akt activity and lipogenesis. Free Raptor levels in liver decline with age and
in obesity; restoration of free Raptor levels reduces liver triglyceride content, through reduced
b-TrCP-mediated degradation of the Akt phosphatase, PHLPP2. Commensurately, forced
PHLPP2 expression ameliorates hepatic steatosis in diet-induced obese mice. These data
suggest that the balance of free and mTORC1-associated Raptor governs hepatic
lipid accumulation, and uncover the potentially therapeutic role of PHLPP2 activators in
non-alcoholic fatty liver disease.
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O
besity-induced metabolic dysfunction manifests as
multiple chronic medical conditions, including type 2
diabetes (T2D) and non-alcoholic fatty liver disease
(NAFLD)1. NAFLD contributes to the overall cardiovascular risk
of obesity2, but is also the most common chronic liver disease,
predisposing to cirrhosis and hepatocellular carcinoma3. Ageing
and obesity are well-established risk factors for NAFLD4, but the
molecular mechanism underlying this risk is poorly defined,
precluding specific pharmacologic strategies to target excess
hepatic triglycerides.
The evolutionarily conserved mechanistic target of rapamycin
(mTOR) is a phosphatidylinositol 3-kinase (PI3K)-like
serine/threonine kinase that regulates cell growth in response to
nutrient signals5, as well as a recently discovered regulatory
role in lipid homoeostasis. Mice with liver-specific deletion of
the mTOR complex 1 (mTORC1)-defining subunit Raptor
(L-Raptor) show reduced SREBP (sterol regulatory element
(SRE)-binding protein)-1c-dependent de novo lipogenesis
(DNL) and are thus protected from fatty liver6. Inhibition of
mTOR/Raptor interaction with the allosteric mTORC1 inhibitor
rapamycin similarly blocks insulin-dependent SREBP1c
activation in primary rat hepatocytes and liver7–9. Consistently,
SREs are highly enriched in promoters of rapamycin-sensitive
genes10, leading to the conclusion that mTORC1 is required for
the lipogenic actions of insulin.
Surprisingly, mice with liver-specific deletion of Tsc1 (L-Tsc1),
the endogenous inhibitor of mTORC1, are also spared from
both age- and diet-induced hepatic steatosis9. The molecular
mechanism underlying this apparent contradictory result was
discovered to be feedback inhibition preventing normal activation
of the serine–threonine kinase Akt9, which then interferes with
SREBP1c function via modulation of Insig2a expression11,12. Akt
is a critical molecular node in insulin signal transduction to
both gluconeogenic and lipogenic liver pathways9,13,14. As such,
mice lacking both hepatic Akt isoforms show marked defects
in both insulin-mediated metabolic processes in liver—glucose
intolerance15, primarily but not exclusively due to loss of
its inhibitory action on the gluconeogenic transcription factor
FoxO1 (ref. 16), as well as a similar reduction in feeding-induced
Srebp1c expression as mice lacking hepatic insulin receptor17.
Collectively, these results point to Akt activity as a key regulator
of insulin action in liver, and suggest that it affects DNL via both
mTORC1-dependent and -independent mechanisms.
Akt is primarily regulated by post-transcriptional means—
insulin stimulation of PI3K induces membrane localization,
unmasking Thr308 for phosphorylation by PDK1, which then
triggers mTORC2 (mTOR complex 2)-mediated phosphorylation
at Ser473 (refs 18,19). While the necessity for both Thr308/Ser473
phosphorylation events in physiologic Akt activation is
well-established20–22, mechanisms accounting for termination
or negative regulation of Akt signalling are far less understood.
Our lab has shown that altered mTORC1 complex stability is
associated with increased Akt activity23—although this phenotype
may be attributed to circumvention of normal nutrient-regulated
mechanisms of mTORC1 catalytic activity and feedback
regulation of Akt24, we hypothesized that mTORC1 stability
has an additional, indirect role to terminate the Akt signal.
Herein we show that Raptor exists in both the
mTORC1-bound and -independent (‘free’) state in liver of young,
healthy mice, but that free Raptor levels decline markedly in
ageing and obesity, coupled with increased Akt activity and
hepatic triglyceride. Moderate hepatic Raptor overexpression to
correct the free Raptor deficit reversed Akt hyperactivity,
decreasing DNL and hepatic triglyceride accumulation by
increasing protein stability of the recently identified Akt Ser473
phosphatase Pleckstrin homology (PH) domain leucine-rich
repeat protein phosphatase 2 (PHLPP2)25,26. Raptor
overexpression prevents aging- or high-fat diet (HFD)-mediated
reductions in PHLPP2 levels, without adversely affecting either
mTORC1/2 activity or whole-body glucose homoeostasis.
Consistently, mild hepatic PHLPP2 overexpression reduced
lipogenic gene expression and obesity-induced triglyceride
accumulation, without affecting glucose tolerance. These data
suggests an important modulatory action of the balance in free
and mTORC1-bound Raptor in the bifurcation model of hepatic
insulin action, as well as point to PHLPP2 as a novel therapeutic
target for NAFLD.
Results
Free Raptor levels decline in aged and obese liver. mTORC1
complexes are affected by hormonal signals and oxidative
stress24,27, likely through direct effects on mTORC1 subunits, and
modulated by other upstream signals, such as IPMK and
Notch23,28. These data suggest that the mTOR/Raptor
interaction is fluid. As liver-specific Raptor (L-Raptor) knockout
mice show aging-dependent defects in ketogenesis29 and
obesity-dependent reductions in lipogenesis6, we hypothesized
that mTORC1 component interaction may be altered in these
pathophysiologic processes. We performed size-exclusion
chromatography to fractionate detergent-free liver lysate from
young mice, and in parallel, older or leptin-deficient (ob/ob)
obese mice. In all three groups of mice, mTOR and GbL eluted in
high-molecular weight (B800 kDa) fractions (Fig. 1a,b),
consistent with mTORC1 complex dimers27,30,31. Raptor was
also found mostly in high-molecular weight fractions in older or
obese mice, but livers from young mice showed a surprising
amount of ‘free’ (B150 kDa) Raptor (Fig. 1a,b). We next
sought confirmation of this finding using alternative
biochemical methods. We exposed liver lysate to a
cell-permeable, non-cleavable chemical cross-linker to trap
native mTORC1 complexes, and again observed a marked
decrease of free Raptor with aging or obesity, without change in
other mTORC1/2 component distribution (Fig. 1c,d and
Supplementary Fig. 1a–c). As total levels of mTOR and Raptor
did not substantially change, we hypothesized that altered free
Raptor reflected greater mTOR–Raptor association in aging or
obesity. To test this, we exposed liver lysate to a cleavable
cross-linker to ensure complete recovery of mTORC1
components. As predicted, whereas the interaction between
mTOR and GbL was unchanged, mTOR–Raptor association
was markedly increased in ob/ob mice (Supplementary Fig. 1d).
Consistently, performing anti-mTOR immunoprecipitation using
CHAPS detergent to sustain the mTOR–Raptor interaction in the
absence of cross-linker24, we found greater bound Raptor in ob/ob
mice (Supplementary Fig. 1e).
Although the disappearance of free Raptor in the liver from
aging or obese mice was consistent across multiple experimental
platforms, we remained skeptical, as various in vitro
manipulations have been shown to affect biochemical recovery
of mTORC1 complexes without true impact on mTOR–Raptor
binding24,32. For instance, transient amino acid deprivation
increases, while rapamycin treatment decreases immuno-
precipitation efficiency of Raptor (Supplementary Fig. 1f), but
neither stimulus altered free Raptor levels (Fig. 1e). This suggests
that our observation of free Raptor in young liver is likely through
a novel mechanism, and that nutrient and/or hormonal signals
prompts a true change in Raptor–mTOR association.
We investigated this possibility in vitro, to dissociate the
various components of obesity and found that while transient/
chronic hyperglycaemia or brief insulin exposure were ineffectual,
prolonged high-dose insulin treatment to induce insulin
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resistance33 reduced free Raptor (Fig. 1f and Supplementary
Fig. 1g). Thus, hepatocyte insulin resistance is sufficient to reduce
free Raptor levels.
Rescue of free Raptor levels prevents hepatic steatosis. We next
hypothesized that loss of free Raptor in the insulin-resistant state,
beyond the above correlation, may be causative to aging/obesity-
induced metabolic dysfunction, which in liver manifests as
excessive triglyceride content, or hepatic steatosis. To test this, we
transduced adult mice with adenovirus encoding Raptor
(Ad-Raptor) or green fluorescent protein (GFP) control
(Ad-GFP) to acutely increase the hepatic Raptor/mTOR ratio,
and increase free Raptor levels (Fig. 2a). As a further internal
control, we transduced young mice, which have ‘normal’ free
Raptor levels (Supplementary Fig. 2a). While we observed no
benefit in young mice, suggestive of a threshold effect of free
Raptor, aging-induced hepatic triglyceride accumulation was
blocked by Ad-Raptor delivery (Fig. 2b). To push the hypothesis
further, we repeated the experiment in aged (12-month-old) or
diet-induced obese (DIO) mice, which have further elevations in
hepatic triglyceride as compared with young or adult mice
(Supplementary Fig. 2b). Remarkably, acute increase in free
Raptor levels reduced liver triglyceride and liver weight in
both aged (Fig. 2c and Supplementary Fig. 2c) and DIO mice
(Fig. 2d and Supplementary Fig. 2d), proving that the observed
free Raptor deficit in these states has biological consequence, as
replacement can ameliorate aging/obesity-induced hepatic
steatosis.
Given the known hepatocyte tropism of adenovirus34, we
hypothesized that free Raptor protects from steatosis through a
cell–autonomous mechanism, consistent with unchanged body
weight, adiposity and plasma fatty acids in Ad-Raptor mice
(Supplementary Fig. 3a–c). Liver Acox and Cpt1a gene expression
and plasma ketone levels were unchanged (Supplementary
Fig. 3d,e), indicative of normal b-oxidation/ketogenesis. Plasma
triglyceride was lower in Ad-Raptor mice (Fig. 2e), implying no
increase in hepatic triglyceride secretion as very-low-density
lipoprotein. Finally, to test DNL, we injected 3H2O into
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Figure 1 | Free Raptor levels decline in aged and obese liver. (a,b) Western blot from livers of young (8-week-old), adult (24-week-old) and ob/ob
(8-week-old) male mice, following size-exclusion chromatography (a) and quantification of signal per fraction (b), normalized to total protein.
(c,d) Western blot from livers of young, adult and ob/ob male mice, cross-linked with disuccinimidyl suberate (DSS) (c) and quantification of free Raptor
signal (d), as a percentage of control (dimethylsulphoxide (DMSO)-treated liver lysate). (e,f) Western blot from hepatocytes deprived of amino acids or
treated with rapamycin (e), or insulin (f), before disuccinimidyl suberate crosslinking. *Po0.05 as compared with the indicated control by two-way analysis
of variance. All data are shown as the means±s.e.m. All blots are representative of three independent experiments, and samples within each group chosen
randomly.
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label into newly synthesized hepatic fatty acid. We found that
adult mice had higher rates of lipogenesis than young mice, but
this was reversed by correcting the aging-related free Raptor
defect (Fig. 2f). Consistently, we observed reduced expression
of Srebp1c, the master regulator of lipogenesis, as well as
its transcriptional targets in Ad-Raptor-transduced liver
(Fig. 2g) and primary hepatocytes (Supplementary Fig. 3f).
Free Raptor reduces Akt-mediated lipogenesis. We next
investigated the molecular mechanism underlying free Raptor-
mediated reduced lipogenesis. Data from rapamycin-treated
hepatocytes and from L-Raptor mice has proven that mTORC1
activity is necessary for normal hepatic Srebp1c function6,8. If
Raptor overexpression reduces mTORC1 catalytic function in
liver, similar to in vitro effects observed in HEK293 cells24,
we would expect impaired Srebp1c-dependent lipogenesis.
Ad-Raptor-transduced liver, however, showed normal fasted or
refed mTORC1 kinase activity on recombinant 4E-BP1,
phosphorylation of canonical mTORC1 targets and hepatic
protein content (Supplementary Fig. 4a–c), in stark contrast
with the phenotype of L-Raptor mice29. Consistently,
mTORC1-dependent negative feedback on insulin signalling
through IRS1 phosphorylation was unchanged (Supplementary
Fig. 4d). We next tested an alternative hypothesis whereby the
addition of excess Raptor could ‘steal’ shared mTOR components
from mTORC2, and recapitulate the lower hepatic triglyceride
observed in L-Rictor mice21, but we observed normal
mTOR interaction with Rictor and the shared mTORC1/2
component, GbL (Supplementary Fig. 4e). In addition,
Ad-Raptor mice showed normal p-Akt Thr450 and PKCa levels
(Supplementary Fig. 4f,g), which are phosphorylated and
stabilized by mTORC2 (refs 35,36).
Interestingly, we did find that phosphorylation of Akt at
Ser473, another known mTORC2 substrate, was increased by
aging in Ad-GFP, but not Ad-Raptor mice (Fig. 3a). PI3K/PDK1-
mediated phosphorylation at Thr308 was unaffected (Fig. 3b),
but we predicted that decreased Akt Ser473 phosphorylation in
Ad-Raptor mice would be sufficient to reduce Akt kinase
activity37. Indeed, GSK3b Ser9 (Supplementary Fig. 5a)
and general Akt substrate phosphorylation (Supplementary
Fig. 5b) was lower, as was immunoprecipitated Akt kinase
activity on recombinant GSK3b (Fig. 3c). In addition, reduced
Akt activity in Ad-Raptor livers led to a twofold increase in
hepatic Insig2a expression (Supplementary Fig. 5c), supporting
the conclusion that free Raptor regulates Srebp1c-mediated
lipogenesis via an Akt-regulated but mTORC1-independent
pathway9.
Raptor increases PHLPP2 levels to terminate Akt signalling.
Akt Ser473 phosphorylation was not altered in extra-hepatic
tissues of Ad-Raptor mice (Supplementary Fig. 5d), suggesting a
cell-autonomous effect of free Raptor on Akt activity, as opposed
to a whole-body change in insulin sensitivity, consistent with
normal plasma insulin levels (Supplementary Fig. 5e). These
data prompted the hypothesis that Akt Ser473 dephosphorylation
was increased in Ad-Raptor mice. PHLPPs, encoded by Phlpp1,
with two splice variants (PHLPP1a and PHLPP1b), and Phlpp2,
have recently been shown to dephosphorylate Akt Ser473 to
terminate insulin/growth factor action25,26. PHLPP1b and
PHLPP2 are expressed in liver (Supplementary Fig. 6a), but
Raptor overexpression selectively increased PHLPP2 (Fig. 3d).
PHLPP2 levels were unaffected by mTOR inhibitors (Fig. 3e and

































































































































































Figure 2 | Rescue of free Raptor prevents aging- and obesity-dependent hepatic steatosis. (a) Western blot from livers of adult Ad-GFP and Ad-Raptor
male mice, following size-exclusion chromatography. Fractions 24 and 25 correspond to mTORC1-associated (B800 kDa) Raptor, while 34 and 35 to free
(B150 kDa) Raptor. (b–d) Hepatic triglyceride (TG) in young or adult (n¼ 6/group) (b), aged (10- to 12-month-old) (n¼ 7 per group) (c), or DIO (n¼ 5
per group) (d) Ad-GFP and Ad-Raptor male mice. (e–g) Plasma TG (e), hepatic fatty acid synthesis (f) and lipogenic gene expression (g) in young or adult,
Ad-GFP and Ad-Raptor mice, killed after a 16 h fast followed by 4 h refeeding (n¼6 per group). *Po0.05, **Po0.01 as compared with the indicated control
by two-way analysis of variance. All data are shown as the means±s.e.m. All blots are representative of three independent experiments, and samples
within each group chosen randomly.
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knockout (Tsc2 / ) mouse embryonic fibroblasts
(Supplementary Fig. 6c), but are markedly lower in livers of
adult or HFD-fed L-Raptor mice (Supplementary Fig. 6d,e) and in
shRaptor-transduced primary hepatocytes (Supplementary
Fig. 6f). Conversely, acute mTOR knockdown to increase the
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Figure 3 | Free Raptor reduces Akt hyperactivity by stabilizing PHLPP2. (a,b) Western blots from livers of young or adult Ad-GFP and Ad-Raptor mice
killed after a 16 h fast followed by 4 h refeeding. (c) Akt activity on recombinant GSK3b peptide, normalized to immunoprecipitated Akt levels. (d) Western
blot from liver of adult Ad-GFP and Ad-Raptor mice killed after a 16 h fast followed by 4 h refeeding, normalized to b-actin. (e) Western blot from Hepa1c1c7
cells treated with Rapamycin (20 nM) or Torin1 (250 nM). (f) Western blot from primary hepatocytes transduced with Ad-shControl or Ad-shmTOR.
(g) Western blot of cycloheximide (CHX, 50mgml 1)-treated primary hepatocytes transduced with GFP or Raptor adenovirus. Quantification of PHLPP2,
normalized to b-actin, relative to time 0 as 100%. (h,i) Western blot of Raptor (or GFP control)-transduced and/or HA/Ub-transfected primary
hepatocytes following immunoprecipitation with anti-PHLPP2, with or without MG-132. *Po0.05 as compared with the indicated control by two-way
analysis of variance. All blots are representative of three independent experiments, and samples within each group chosen randomly.
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hepatocyte PHLPP2 (Fig. 3f). In summary, these data prove that
free Raptor, but not mTORC1/2 activity, regulates PHLPP2.
Interestingly, Raptor overexpression did not increase Phlpp2
mRNA in liver or primary hepatocytes (Supplementary Fig. 6g,h),
even as it induced protein levels of both basal and exogenous
PHLPP2 (Supplementary Fig. 6i), suggesting an impact of
free Raptor on PHLPP2 stability. Consistent with this
hypothesis, Raptor overexpression maintained PHLPP2 levels in
the face of cycloheximide treatment (Fig. 3g), likely due to
reduced ubiquitin-mediated proteosomal degradation (Fig. 3h).
b-TrCP (beta-transducin repeat-containing protein), the
E3 ligase/substrate recognition subunit of the SCF (Skp1-Cullin
1-F-box protein) protein complex, has been shown to
mediate PHLPP1 degradation in tumours—as this regulation
occurs via the PP2C domain conserved in both PHLPPs38,
we tested PHLPP2-b-TrCP association in primary
hepatocytes and hepatoma cells. Raptor overexpression
markedly diminished proteosomal inhibitor-exposed
PHLPP2-b-TrCP association (Fig. 3i and Supplementary
Fig. 6j). Importantly, PHLPP1 levels or its association with
b-TrCP was not altered (Fig. 3d), suggesting the specificity of free
Raptor’s protection of PHLPP2 from b-TrCP-mediated
proteosomal degradation.
Hepatic PHLPP2 levels decline with aging and in obesity. Free
Raptor levels decline with aging and obesity—consistently,
despite unchanged hepatic Phlpp2 gene expression (Fig. 4a), we
observed lower PHLPP2 protein levels with aging and in dietary
or genetic models of obesity (Fig. 4b–d). To test whether reduc-
tion in hepatic PHLPP2 is sufficient to induce steatosis, we
constructed adenoviruses encoding shRNA targeting either
Phlpp1 (Ad-shPHLPP1) or Phlpp2 (Ad-shPHLPP2). In primary
hepatocytes, knockdown of PHLPP2 but not PHLPP1 increased
Akt Ser473 phosphorylation (Supplementary Fig. 7a). Corre-
spondingly, mice transduced with Ad-shPHLPP2 showed
increased liver weight and hepatic steatosis (Supplementary
Fig. 7b,c), mirroring the phenotype of mice transduced with
constitutively active Akt (Ad-myrAkt)39,40. We next performed
the converse experiment, to test whether adenoviral rescue of
PHLPP2 (Ad-PHLPP2) in DIO mice would inhibit hepatic
lipid accumulation. As expected, Ad-PHLPP2 mice showed
decreased Akt Ser473 phosphorylation (Fig. 4e). In addition,
despite unchanged body weight and adiposity (Supplementary
Fig. 8a,b), Ad-PHLPP2 mice showed decreased liver weight
(Supplementary Fig. 8c) and a trend towards lower hepatic
triglyceride (Fig. 4f) and lipogenic gene expression (Fig. 4g), with
































































































































































Figure 4 | Rescue of lower PHLPP2 in aging or obesity reduces lipogenesis. (a) Liver mRNA expression from young and adult mice (n¼6 per
each group). (b–d) Western blot from livers of young and adult (b), chow- and HFD-fed (c), or lean and ob/ob (d) mice, normalized to b-actin.
(e–h) Western blots from liver (e), hepatic triglyceride (f), liver lipogenic gene expression (g) and plasma lipids (h) in adult, HFD-fed Ad-GFP
or Ad-PHLPP2 mice (n¼6–7/group). *Po0.05, **Po0.01 as compared with the indicated control by two-way analysis of variance. All data are shown
as the means±s.e.m.
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These data suggest that preservation of free Raptor, via
PHLPP2, can prevent hepatic steatosis, but to prove this,
we co-transduced Ad-Raptor (or Ad-GFP control) mice with
Ad-shControl, Ad-shPHLPP1 or Ad-shPHLPP2 adenoviruses.
PHLPP2 knockdown restored Akt Ser473 phosphorylation in
Ad-Raptor mice (Fig. 5a), resulting in hepatic and plasma
triglyceride levels comparable to control mice (Fig. 5b,c), without
altering body weight/adiposity or other serum metabolites
(Supplementary Fig. 9a–d). PHLPP2 knockdown restored
lipogenic gene expression (Fig. 5d), without affecting canonical
mTORC1/2 signalling or activity (Supplementary Fig. 9e).
Interestingly, Ad-myrAkt transduction in Ad-Raptor mice
similarly increased liver triglyceride (Fig. 5e), buttressing our
conclusion that free Raptor maintains normal hepatic lipogenesis/
triglyceride content by increasing PHLPP2, to restrict Akt
activation.
Reduced hepatic Akt activity is typically associated with
hyperglycaemia41. Surprisingly, but consistent with the
phenotype of Ad-Raptor mice (Supplementary Fig. 10a–c),
Ad-PHLPP2 mice showed normal glucose tolerance (Fig. 5f)
and similar glucose and insulin levels as compared with control
mice (Supplementary Fig. 10d,e). These data suggest that free
Raptor, via PHLPP2, selectively regulates Akt’s effects on
lipogenesis, while leaving intact Akt repression of hepatic
glucose production.
Discussion
Although mTOR and Raptor expression tends to be tightly
linked24, the association between these catalytic and
primary scaffolding subunits of the mTORC1 complex is
far more dynamic. Elegant biochemistry has shown that
amino acid deprivation tightens, while rapamycin treatment
loosens but does not break the mTOR–Raptor interaction24,32.
While in vitro studies have hinted of the presence of
an mTORC1-independent Raptor species27,42, our data proves
for the first time the existence, and modulation by
pathophysiologic (aging, obesity) stimuli, of free Raptor.
Further study is required to determine whether free Raptor
exists due to failure in association or true dissociation
from mTOR, and whether the free and mTORC1-bound
Raptor pools may interchange. In addition, what upstream
signals (for example, alternative protein–protein interaction or a,
post-translational modification on Raptor or another mTORC1
complex member) govern these event(s), and whether free Raptor
affects other cellular processes are important questions that our
lab is actively pursuing. Nevertheless, this first report of
mTORC1-independent Raptor function suggests that its
heretofore accepted role as a simple scaffold for mTOR
catalytic activity is an oversimplification, and should prompt re-
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Figure 5 | Reduced liver triglyceride (TG) by free Raptor is PHLPP2-dependent. (a–d) Western blots from liver (a), hepatic TG (b), plasma TG
(c) and liver lipogenic gene expression (d) of adult Ad-GFP and Ad-Raptor mice co-transduced with control (Ad-shControl), Ad-shPHLPP1 or
Ad-shPHLPP2 adenoviruses, killed after a 16 h fast followed by 4 h refeeding (n¼6 per group). (e) Hepatic TG from liver of adult Ad-GFP and
Ad-Raptor mice co-transduced with control (GFP) or myrAkt adenovirus, killed after a 16 h fast followed by 4 h refeeding (n¼6 per group). (f) GTT in
adult, HFD-fed Ad-GFP or Ad-PHLPP2 mice (n¼ 6–7 per group). *Po0.05, **Po0.01 as compared with the indicated control by two-way analysis
of variance. All data are shown as the means±s.e.m. All blots are representative of three independent experiments, and samples within each group
chosen randomly.
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The Raptor/PHLPP2 axis provides yet another mechanism of
interplay, albeit indirect, between the insulin/Akt and nutrient/
mTOR pathways9,21,37. While there are likely additional
determinants of hepatic PHLPP2, as evidenced by residual
levels in L-Raptor livers, we postulate that insulin-Akt
signalling, via free Raptor, may be responsible for its own
regulation by PHLPP2. In fact, several predicted Akt and
GSK3b phosphorylation sites exist in the C terminus of
PHLPP2 within a b-TrCP-mediated destruction motif
(phosphodegron), suggesting an Akt-dependent negative
feedback loop to determine post-translational PHLPP2 stability
to regulate Akt activity in obese liver. Conversely, a modest free
Raptor-induced increase in PHLPP2 levels can reduce
Akt-regulated DNL via increased Insig2a expression, but
remarkably, does not impair glucose homoeostasis. This is
striking contrast to the phenotype of hepatic mTORC2-deficient
(and thus Akt Ser473 phosphorylation-incompetent) L-Rictor
mice21, which fail to maximally activate Akt, leading to
unchecked hepatic glucose output and glucose intolerance,
closely approximating ‘complete’ hepatic insulin resistance43,44.
Integrating these data, we propose a new model of insulin action
(Fig. 6) whereby Akt must be appropriately stimulated, but also
inactivated by PHLPP2 in a timely fashion, to maintain normal
hepatic physiology. Our model is consistent with the ‘bifurcation’
model of insulin signalling proposed by Brown & Goldstein13,
and others17, but differs in the kinetics of events—inhibition of
FoxO1 to repress gluconeogenesis is an ‘early’ event and requires
the full force of Akt action45, but an extension of Akt activity by
maintained Ser473 phosphorylation induces the ‘late’ lipogenic
response by mTORC1-dependent13 and -independent9 pathways.
PHLPPs have been the subject of considerable research in
recent years, due to their therapeutic potential in neoplastic
disease. Loss-of-heterozygosity has been observed at both PHLPP
loci in multiple solid tumours46 and a common PHLPP2 loss-of-
function variant shown to reduce Akt dephosphorylation47 has
been observed in high-grade breast cancers. In combination
with the known oncogenic role of Akt, these findings suggest that
PHLPPs may have tumour suppressor activity. Enthusiasm for
pharmacologic PHLPP activators, such as HDAC3 inhibitors48 or
adenylate cyclase activators49, has been tempered by speculated
interference with normal Akt function and potential to cause
new-onset T2D46, consistent with epidemiologic studies showing
increased PHLPP1, but importantly not PHLPP2, expression in
adipose or muscle of obese/T2D50,51. Our, gain- and loss-of-
function studies show that PHLPP1 has little function in liver,
whereas hepatic PHLPP2 levels/activity dissociate Akt functions
in liver to reduce lipogenesis without adversely affecting glucose
tolerance. Our data would suggest that application of putative
PHLPP2 agonists or liver-specific delivery of non-specific PHLPP
activators52 have the potential to stem the tide of obesity-induced
NAFLD.
Methods
Experimental animals. 8-week-old male wild-type C57/BL/6 mice fed on standard
chow or HFD were purchased from Jackson Labs. We injected AAV8-TBG-GFP or
AAV8-TBG-Cre (Penn Vector Core) into male Raptorflox/flox (Jackson Laboratory;
stock number 013188) mice fed on standard chow or HFD, and characterized the
mice at 2 weeks after AAV injection. Number of animals used in experiments was
chosen to ensure adequate power to detect experimental difference with alpha set
to 0.05. All animal experiments were conducted in accordance with guidelines of,
and were explicitly approved by, the Columbia University Institutional Animal
Care and Use Committee.
Metabolic analyses. Blood glucose (blood taken from tail vein) was measured
using a glucometer (OneTouch) and plasma insulin concentrations were measured
using a mouse insulin ELISA kit (Mercodia). Glucose tolerance tests were
performed by intraperitoneal injection of 2 g per kg body weight glucose after a
16 h fast. Hepatic lipids were extracted by the Folch method53, and plasma and
hepatic triglyceride, Cholesterol E and non-esterified fatty acid were measured
using a colorimetric assay from Thermo or Wako Chemicals, according to the
manufacturer’s protocol. We measured hepatic DNL by measuring the amount of
newly synthesized fatty acid present in the liver 1 h after intraperitoneal injection of
1mCi of 3H2O (ref. 54).
Gel filtration chromatography and crosslinking assay. Liver tissues from three
independent mice were pooled and lysed in hypotonic buffer (40mM Tris-HCl
(pH 7.5))42 including protease inhibitors (Pierce) by repeated passage with a
27-gauge needle. The lysates were centrifuged at 14,000 r.p.m. for 15min, and
the supernatants were further centrifuged. The supernatant fraction was filtered
with a PVDF membrane and then applied to a Superose 6 column (Amersham
Biosciences) and eluted with 40mM Tris-HCl (pH 7.5) and 150mM NaCl.
The column was calibrated with the Gel Filtration Marker Kit (Sigma).
Liver tissues were lysed in 1% Triton X-100 lysis buffer24 including
protease and phosphatase inhibitors with or without 2.5mgml 1
dithiobis[succinimidylpropionate] or disuccinimidyl suberate (Pierce), and
incubated for 2 h on ice. Crosslinking reactions were quenched by adding 1M
Tris-HCl (pH 7.5) followed by an additional 30min incubation. For in vivo
crosslinking assays, dithiobis[succinimidylpropionate] or disuccinimidyl suberate
were added to a final concentration in the cell culture medium of 1mgml 1 and
reactions quenched by adding Tris-HCl (pH 7.5). Equal protein amounts were then
analysed by either immunoprecipitation or immunoblotting directly.
Adenovirus studies. The GFP, Raptor and PHLPP1/2 adenoviruses have been
described23,55. The HA-Flag-PHLPP2 adenovirus was constructed by inserting a
Flag sequence into HA-PHLPP2 vector (Addgene #22403, courtesy of Alexandra
Newton) and adenoviruses encoding HA-Flag-PHLPP2 generated by Welgen, Inc.
(Worcester, MA). Mouse shPhlpp1 or 2 target sequences were selected among
three candidate sequences, respectively, and adenoviruses encoding shPhlpp1 or 2
generated by Welgen, Inc. Adenovirus expressing shmTOR, shRaptor and shRictor
was generated by homologous recombination between pAd-Easy1 and pAd-Track
vector. For in vivo studies, we injected 5 108 or 2.5 108 purified viral particles
per gram body weight; we performed metabolic analysis on days 3–5 and killed the
mice at day 8 or 10 after injection. Infection with adenovirus in primary
hepatocytes or Hepa1c1c7 cells was performed at 2.5, 5, or 10 multiplicity of
infection.
Primary hepatocyte cultures. Primary mouse hepatocytes were isolated as
previously described56—in brief, mice were anaesthetized with a ketamine/xylazine
mixture (Sigma), abdominal cavity exposed and inferior vena cava catheterized
with a 23-gauge catheter (Becton Dickinson). The superior vena cava was clamped,
portal vein was transected and Hepes-based perfusion solution infused into the
liver for 2min at 5 ccmin 1 followed by type I collagenase (Worthington
Biochemicals), including protease inhibitor caplets (Boehringer Mannheim), for
18min at the same flow rate. Liver cells were filtered, mixed with Percoll and spun
at 100 g to remove dead cells and non-hepatocytes. After two washes, cells were
plated at 0.8 106 cells per well of six-well dish in Williams E supplemented with














Figure 6 | A proposed model of free Raptor-mediated regulation of
hepatic lipogenesis. Akt represents the common molecular hub of insulin
regulation of hepatic glucose production and lipogenesis. In the post-
prandial state, Akt-mediated FoxO nuclear exclusion occurs rapidly, after
which Akt is dephosphorylated by PHLPP2 at Ser473 to terminate insulin
action. In aging or obesity, loss of free Raptor destabilizes PHLPP2, leading
to prolonged Akt activity and Srebp1c-dependent lipogenesis.
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rapamycin (Cell Signaling), 250 nM Torin1 or vehicle for either 1 or 24 h. The
construct expressing HA/Ub was transfected using Lipofectamine 3000
(Invitrogen) according to the manufacture’s recommendation.
Western blotting and co-immunoprecipitation. Liver tissues or cells were lysed
in a Triton-based or 0.3% CHAPS lysis buffer24 and whole-cell lysates were
obtained by subsequent centrifugation. Immunoblots were conducted on 3–5
samples randomly chosen within each experimental cohort with antibodies against
Raptor (#2280), Akt (#9272), p-Akt (S473, #4060), p-Akt (T308, #9275), p-Akt1
(S473, #9018), p-Akt2 (S474, #8599), p-Akt (T450, #12178), p-Akt substrate
(#9614), PKCa (#2056), p-GSK3b (S9, #9336), GSK3b (#9315) mTOR (#2983),
Rictor (#2140), GbL (#3274), p-S6 (S240/244, #2215), S6 (#2217), p-4E-BP1 (T37/
46, #2855), b-TrCP (#4394), p-IRS1 (S636/639, #2388) and b-actin (#4970) from
Cell Signaling; mTOR (sc-1549) and a-tubulin (sc-12462) from SantaCruz
Biotechnology, Inc.; PHLPP1 (A300-660A) and PHLPP2 (A300-661A) from Bethyl
Laboratories, Inc.; a polyclonal antibody against Raptor (#42-4,000) from
Invitrogen; as well as Protein A-HRP (10-1,023) from Pierce. Primary antibodies
were used at a 1:1,000 dilution. Uncropped images for all western blots can be
found in Supplementary Fig. 11. For co-immunoprecipitation assays, liver extracts
or cells were mixed with anti-mTOR or PHLPP2 antibody immobilized on Protein
A or G-Sepharose (Invitrogen).
Quantitative reverse transcription PCR. We isolated RNA with TRIzol
(Invitrogen) or an RNeasy Mini kit (Qiagen), synthesized complementary DNA
with High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) and
performed quantitative reverse transcription PCR with a GoTaq SYBR Green qPCR
kit (Promega) in a CFX96 Real-Time PCR detection system (Bio-Rad). Primer
sequences are available in Supplementary Table 1.
In vitro mTORC1 or Akt kinase assay. Liver lysates were immunoprecipitated
with anti-mTOR or anti-Akt antibody (sepharose bead conjugated) and the
immunoprecipitates were incubated with 4E-BP1 or GSK3 fusion protein substrate
in kinase buffer for 30min at 30 C. Reactions were terminated by SDS loading
buffer. The samples were separated on SDS–PAGE, and the p-4E-BP1 (T37/46) or
p-GSK3b (S9) was detected by immunoblot.
Statistical analysis. We performed comparisons using two-way analysis of
variance. All data are shown as the means±s.e.m.
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